Skip to main content

Loratadine: A Potent, Nonsedating, and Long-Acting H1 Antagonist

The full text article is temporarily unavailable.

We apologise for the inconvenience. Please try again later.

Loratadine, a nonclassical selective, peripheral H1-receptor antagonist has undergone extensive preclinical studies and clinical trials in over 6,000 patients. In the treatment of allergic rhinitis, loratadine has efficacy equivalent to clemastine, terfenadine, astemizole, and mequitazine. Its duration of action is 18–24 hours making once daily dosing practical. Loratadine is virtually devoid of sedating or other CNS effects.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Publication date: 01 July 1987

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more